Moe Thuzar

Moe Thuzar (MBBS, FRCP UK, FRACP, PhD) is a Senior Endocrinologist at the Princess Alexandra Hospital (PAH), the Director of Translational Engagement at the Translational Research Institute (TRI, and a Senior Research Fellow at the Faculty of Medicine, University of Queensland, Brisbane. She is the clinical & research Lead in Adrenal Endocrinology in the Endocrinology Department at the PAH, and has a strong research interest in the Neuroendocrine Regulation of Metabolism and Cardiovascular Health in Humans, particularly the Adrenal Endocrine System and Primary Aldosteronsim.

After completing her specialist training and receiving FRACP (Fellowship of the Royal Australasian College of Physicians) in early 2014, she undertook her PhD study (2014-2018, UQ) investigating the role of adrenal neuroendocrine system in the regulation of human brown adipose tissue and energy metabolism under the primary supervision of Professor Ken Ho. Moe then joined the Endocrine Hypertension Unit of Professor Michael Stowasser, pursuing further research in Cardiovascular Endocrinology, in particular, elucidating the role of the mineralocorticoid system in the regulation of cardiometabolic health and its interplay with other systems in humans, and investigating optimal diagnostic and management strategies for primary aldosteronism. She joined the Executive Leadership Team of the TRI as the Director of Translational Engagement in 2026, providing strategic leadship for programs fostering partnerships between scientists, clinicians, industry and consumers, and an innovative ecosystem acclerating discoveries into clinical solutions.

Her research has informed a number of National and International Clinical Practice Guidelines including the US Endocrine Society's Guidelines for Diagnosis and Management of Primary Aldosteronism (2025), Lipid Management in Patients with Endocrine Disorders (2020), the Chinese Society of Cardiology/Chinese Medical Association's Joint Guideline for Management of Hypertension (2024), Australian & New Zealand Guideline for Adrenal Venous Sampling in Primary Aldosteronism (2025), the Endocrine Society of Australia/Australian Association of Clinical Biochemist/Royal Australasian College of Pathologists' Joint Guideline for Endocrine Dynamic Testing (2021), QLD Statewide Protocol for Management of Diabetes Ketoacidosis (2014).

She has received numerous awards for her work including US Endocrine Society’s Presidential Awards for Excellence in Cardiovascular Endocrinology Research (2017) and in Adipocyte Biology Research (2017), Early Career Researcher Award from the Australian & New Zealand Obesity Society (2016), Australasian Women in Endocrinology Young Investigator Award (2017), Queensland Health & Medical Research Award (Previously “Premier’s award”, finalist, 2017), Young Investigator Award, International Aldosterone Conference (runner-up, 2019), Endocrine Society of Australia's Paul Lee Award (2023). She is a Principal Investigator (PI) or Chief Investigator (CI) of a number of successful competitive grants, totalling ~4 millions to date, which include Royal Australasian College of Physicians-Australian Diabetes Society Research Establishment Fellowship (2023), MRFF Clinician Researchers Project Grant (CI, 2022-2025), Metro South Research Support Scheme Program Grant (PI, 2021-2023), Diabetes Australia Project Grant (PI, 2019-2021), Metro South Research Support Scheme Early Career Researcher Grant (PI, 2019-2022), Endocrine Society of Australia Postdoctoral Fellowship (2019). She has served as an expert reviewer for Grant review panels including UK Research & Innovation Grants Scheme, NHMRC Project Grants Scheme and for top journals in the field, and held editorial roles for a number of journals including the Frontiers in Endocrinology, Metabolites.